Grace Therapeutics financials
$2.11−0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$15.9M | -$3.0M | -$2.4M | -$2.5M | -$3.1M | -$3.2M | -$3.7M |
| Net income | -$15.8M | -$1.2M | -$2.3M | -$938.0K | -$3.4M | $636.0K | -$4.2M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.91 | $-0.07 | $-0.14 | $-0.06 | $-0.21 | $0.04 | $-0.36 |
| EBITDA | -$2.4M | -$3.0M | -$2.4M | -$2.5M | -$3.1M | -$3.2M | -$3.7M |
| Operating cash flow | -$3.2M | -$1.7M | -$2.2M | -$3.1M | -$1.8M | -$3.0M | -$4.1M |
| Free cash flow | -$3.2M | -$1.7M | -$2.2M | -$3.1M | -$1.8M | -$3.0M | -$4.1M |
| Diluted shares | 17.3M | 17.3M | 16.9M | 15.9M | 15.9M | 14.4M | 11.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.8M | $17.0M | $18.7M | $16.9M | $20.0M | $22.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $50.1M | $66.7M | $68.5M | $66.6M | $69.8M | $72.0M |
| Total liabilities | $1.9M | $2.8M | $3.6M | $3.8M | $6.3M | $5.4M |
| Shareholders' equity | $48.2M | $63.9M | $64.9M | $62.8M | $63.5M | $66.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology